Why the study?
Mutations in phospholamban (PLN) are linked to familial dilated cardiomyopathy (DCM) and heart failure, but the underlying molecular mechanism remains controversial.
Structural analysis reveals that DCM-associated mutations in phospholamban reduce its phosphorylation by PKA through altered conformation and weakened binding, providing a molecular mechanism for familial dilated cardiomyopathy.
Should not yet change familial DCM care; challenges PKA-sequestration models and leaves open phosphorylation-restoring strategies.
Several mutations identified in phospholamban (PLN) have been linked to familial dilated cardiomyopathy (DCM) and heart failure, yet the underlying molecular mechanism remains controversial. PLN interacts with sarco/endoplasmic reticulum Ca 2+ -ATPase (SERCA) and regulates calcium uptake, which is modulated by the protein kinase A (PKA)-dependent phosphorylation of PLN during the fight-or-flight response. Here, we present the crystal structures of the catalytic domain of mouse PKA in complex with wild-type and DCM-mutant PLNs. Our structures, combined with the results from other biophysical and biochemical assays, reveal a common disease mechanism: the mutations in PLN reduce its phosphorylation level by changing its conformation and weakening its interactions with PKA. In addition, we demonstrate that another more ubiquitous SERCA-regulatory peptide, called another-regulin (ALN), shares a similar mechanism mediated by PKA in regulating SERCA activity.
No takes yet. Share an insight, caveat, or question.
A 2022 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: